-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche’s Genentech To Present Pivotal Lung And Breast Cancer Data At ESMO 2026, Highlighting Divarasib Superiority Over Standard Of Care And Giredestrant Efficacy Gains Without Tolerability Or Quality-Of-Life Compromise

Benzinga·10/19/2026 06:29:33
Listen to the news
  • Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors, in previously treated advanced G12C-mutated non-small cell lung cancer
  • Patient-reported outcomes from Phase III lidERA study showed improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer
  • Second Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3 targeted ADC, to deliver robust efficacy with a favorable safety profile in high-unmet-need solid tumors